Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Diluted Average) (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $129.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 4.8% year-over-year to $129.9 million, compared with a TTM value of $129.9 million through Dec 2025, up 4.8%, and an annual FY2025 reading of $129.9 million, up 4.8% over the prior year.
  • Shares Outstanding (Diluted Average) hit $129.9 million in Q4 2025 for Apellis Pharmaceuticals, up from $125.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $129.9 million in Q4 2025, with the low at $79938.0 in Q2 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $117.2 million (2023), compared with a mean of $78.8 million.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 109244.46% in 2023, then grew 1.87% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $84.4 million in 2021, then rose by 25.7% to $106.1 million in 2022, then increased by 11.84% to $118.7 million in 2023, then grew by 4.4% to $123.9 million in 2024, then rose by 4.8% to $129.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $129.9 million, $125.7 million, and $125.5 million for Q4 2025, Q2 2025, and Q1 2025 respectively.